Contact Information: FOR FURTHER INFORMATION, CONTACT: Michael Brennan Chairman Micro Imaging Technology, Inc. Email: Email Contact Phone: (805) 557-0614
Micro Imaging Technology Announces an OEM Agreement With JMAR Technologies
| Source: Micro Imaging Technology, Inc.
SAN CLEMENTE, CA -- (MARKET WIRE) -- January 9, 2007 -- Micro Imaging Technology, Inc. (OTCBB : MMTC ) announced that it has entered into an OEM supply agreement with JMAR
Technologies, Inc. ("JMAR"). MIT's system for the rapid identification of
E. coli, Listeria, Salmonella and other pathogens will be purchased and
offered as an option with JMAR's BioSentry™ product line.
Michael Brennan, MIT's Chairman, stated that, "The combined technologies
have a wide-ranging impact; JMAR's BioSentry™ instantly determines if
there is a contaminant within a water supply and, within minutes after the
contaminant is isolated, the accompanying MIT system will identify the
specific species of bacteria, protozoa, fungi or other parasite present in
the water. This agreement enables JMAR to sell MIT's table-top, rapid
microbial identification system either as a complement to its BioSentry™
Water Monitoring System or as a stand-alone unit for customer laboratory
sample evaluation. MIT expects to supply numerous systems over the next
eighteen months with initial deliveries in January."
About JMAR:
JMAR is a leading innovator in the development of laser-based technology
and x-ray processes for nano-scale imaging, analysis and fabrication. The
Company is leveraging more than a decade of laser and photonic research to
develop a portfolio of products with commercial applications in rapidly
growing industries, while continuing to carry out research and development
for the U.S. Government.
JMAR's flagship product, BioSentry™, is a patented contamination warning
system for waterborne microorganisms. BioSentry™ was developed by Sensor
Technologies, Inc. -- a division of JMAR -- and uses laser-based,
multi-angle light scattering technology to provide continuous, on-line,
real-time monitoring for harmful microorganisms. BioSentry™ is targeted
toward a number of applications across multiple markets, including homeland
security, the cruise ship and beverage industries, pharmaceutical
companies, and municipal water utilities.
About Micro Imaging Technology:
MIT has developed and patented a laser-based technology for rapid microbe
detection and identification. The system measures scattered light intensity
as individual microbes pass through a laser beam. The intensity pattern of
the scattered light is a direct consequence of the size, shape and external
and internal optical characteristics of the microbe. The MIT system is
non-biological, does not rely on biological agents, conventional chemical
processing, fluorescent tags, gas chromatography or DNA analysis and
combines extremely low test costs and fast completion times with very
simple operating procedures.
MIT has demonstrated the ability to detect and identify, within minutes,
the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus,
Shigella and other pathogenic bacteria and protozoa; including
Cryptosporidium and Giardia. The identification process has been tested and
verified by North American Science Associates, Inc. (NAMSA), an independent
and internationally recognized testing and certification laboratory. The
NAMSA Test Report, available from the Company, confirms the accuracy, speed
and efficiency of the MIT system over conventional processes.
This release contains statements that are forward-looking in nature.
Statements that are predictive in nature, that depend upon or refer to
future events or conditions or that include words such as "expects,"
"anticipates," "intends," "plans," "believes," "estimates," and similar
expressions are forward-looking statements. These statements are made
based upon information available to the Company as of the date of this
release, and we assume no obligation to update any such forward-looking
statements. These statements are not guarantees of future performance and
actual results could differ materially from our current expectations.
Factors that could cause or contribute to such differences include, but are
not limited to dependence on suppliers; short product life cycles and
reductions in unit selling prices; delays in development or shipment of new
products; lack of market acceptance of our new products or services;
inability to continue to develop competitive new products and services on a
timely basis; introduction of new products or services by major
competitors; our ability to attract and retain qualified employees;
inability to expand our operations to support increased growth; and
declining economic conditions, including a recession. These and other
factors and risks associated with our business are discussed from time to
time within our filings with the Securities and Exchange Commission.